loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Safinamide

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Safinamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,170Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amneal Enters into European Licensing Agreement with Zambon Biotech for IPX203
    Amneal Enters into European Licensing Agreement with Zambon Biotech for IPX203

    27 Feb 2024

    // PRESS RELEASE

    https://www.zambon.com/en/media/press/2024-02-27-amneal-enters-exclusive-european-licensing-agreement-zambon-biotech-ipx203

    PRESS RELEASE
    27 Feb 2024
    Share Share
    Safinamide mesylate by Zambon Co for Multiple System Atrophy Likelihood Approval
    Safinamide mesylate by Zambon Co for Multiple System Atrophy Likelihood Approval

    28 Aug 2023

    // PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/data-insights/safinamide-mesylate-zambon-co-multiple-system-atrophy-msa-or-shy-drager-syndrome-or-multi-system-degeneration-likelihood-of-approval/

    PHARMACEUTICAL TECHNOLOGY
    28 Aug 2023
    Share Share
    Aurobindo's Generic Safinamide Mesylate Receives Approval in the U.S.
    Aurobindo's Generic Safinamide Mesylate Receives Approval in the U.S.

    14 Jun 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215902

    FDA
    14 Jun 2023
    Share Share
    RK Pharma Receives Generic Safinamide Mesylate Approval in the U.S
    RK Pharma Receives Generic Safinamide Mesylate Approval in the U.S

    03 May 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215945

    FDA
    03 May 2023
    Share Share
    Optimus' Generic Safinamide Receives Approval in the U.S.
    Optimus' Generic Safinamide Receives Approval in the U.S.

    12 Jan 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216020

    FDA
    12 Jan 2023
    Share Share
    Optimus' Generic Safinamide Mesylate Receives Approval in the U.S.
    Optimus' Generic Safinamide Mesylate Receives Approval in the U.S.

    12 Jan 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216020

    FDA
    12 Jan 2023
    Share Share